PharmaCyte Biotech (PMCB) Research & Development (2010 - 2026)
PharmaCyte Biotech (PMCB) posted quarterly Research & Development of $61946.0 for Q2 2026, down 51.12% year-over-year from $126734.0 in Q2 2025, and down 33.47% quarter-over-quarter from $93113.0 in Q1 2026.
PharmaCyte Biotech (PMCB) Research & Development (2010 - 2026) Analysis & Trends
PharmaCyte Biotech (PMCB) has reported Research & Development for 17 consecutive years, with $61946.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Research & Development fell 51.12% year-over-year to $61946.0; the TTM figure through Apr 2026 stood at $391301.0 (down 10.75% YoY), while the FY2026 annual figure was $391301.0, down 10.75% from the prior year.
- Research & Development slipped to $61946.0 in Q2 2026 per PMCB's latest filing, from $93113.0 in the prior quarter.
- Across five years, Research & Development topped out at $254065.0 in Q2 2022 and bottomed at $45393.0 in Q1 2023.
- Historically, Research & Development has averaged $117654.9 across 5 years, with a median of $100976.5 in 2023.
- Annual changes were most pronounced in 2023 — Research & Development slumped 71.28% — and 2024, when it surged 179.19%.
- PharmaCyte Biotech's Research & Development stood at $177996.0 in 2022, then plunged by 53.91% to $82033.0 in 2023, then gained by 18.82% to $97470.0 in 2024, then jumped by 44.75% to $141085.0 in 2025, then plunged by 56.09% to $61946.0 in 2026.
- Business Quant data shows PMCB's Research & Development at $61946.0 in Q2 2026, $93113.0 in Q1 2026, and $141085.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.76 Bn | 130.91 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 86.15 Bn | 78.15 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.45 Bn | 59.27 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 57.08 Bn | 51.94 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 42.08 Bn | 36.99 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.90 Bn | 27.59 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 27.76 Bn | 9.37 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.00 Bn | 26.17 Bn | - | 97.90 Mn |
| 10 | PharmaCyte Biotech | 4.32 Mn | 4.32 Mn | - | 61,946.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 61,946.00 |
| Jan 31, 2026 | 93,113.00 |
| Oct 31, 2025 | 141,085.00 |
| Jul 31, 2025 | 95,157.00 |
| Apr 30, 2025 | 126,734.00 |
| Jan 31, 2025 | 118,196.00 |
| Oct 31, 2024 | 97,470.00 |
| Jul 31, 2024 | 96,016.00 |
| Apr 30, 2024 | 94,183.00 |
| Jan 31, 2024 | 126,732.00 |
| Oct 31, 2023 | 82,033.00 |
| Jul 31, 2023 | 104,483.00 |
| Apr 30, 2023 | 85,874.00 |
| Jan 31, 2023 | 45,393.00 |
| Oct 31, 2022 | 177,996.00 |
| Jul 31, 2022 | 159,273.00 |
| Apr 30, 2022 | 254,065.00 |
| Jan 31, 2022 | 158,039.00 |
| Oct 31, 2021 | 135,220.00 |
| Jul 31, 2021 | 143,613.00 |